Jobs

Business briefs: J&J, Manhattan Research, plus July job cuts

J&J sells off its feminine side; Manhattan Research's study on the sales rep "tablet dance"; Cepheid rolls out a consumer TB campaign; and healthcare sector job losses top out in July.

Business briefs: Roche, Doximity and Bayer

Roche is shuttering a division and eliminating 170 jobs; Doximity has added another client; a cautiously-worded study indicates antidepressants may be linked to autism; and NICE has endorsed a new use for Bayer's Xarelto.

Business briefs: Chandler Chicco, Pfizer, FDA, Dainippon, CDC

Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses.

More pink slips at AstraZeneca

By

Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.

Company news: Edelman, Pfizer, Publicis, Lippincott

Healthcare PR giant Dan Edelman dies; Pfizer says 'no comment' on breakup speculation; Publicis Healthcare snags a new SVP; Lippincott gives nurses a new drug diagnosis tool.

Company news: ComScore, Pfizer, J&J

ComScore finds a trend between ads and prescriptions, Pfizer is courting fewer PCPs, Weldon is out as chair in 2013.

Company news: Bristol-Myers Squibb and Regeneron

Bristol-Myers fires, Regeneron hires.

People news: Boston Scientific, Watson

Boston Scientific's new CEO takes office, Watson creates a generics management team

Company news: Pfizer, Johnson & Johnson, TGaS and Roche

Sandy halts earnings reports and trading, Pfizer and J&J slash headcounts, TGaS to-do's for market researchers, Roche probed on pharmacovigilance

Abbott lays off 550 as breakup nears

Abbott lays off 550 as breakup nears

By

The company talked R&D investment strategies for the two new companies during its Q3 earnings call, and has also laid off 550 employees.

What's more important to pharma execs? A large paycheck or a great place to work?

MM&M's 26th annual Career & Salary Survey is now open. Help us to give you the truest picture of salaries, opportunities, migration, aspirations and opinions within pharma and healthcare marketing.

Company news: MedImmune, Waggener Edstrom

Waggener Edstrom hires a new VP and account exec, MedImmune to shutter two California sites.

Abbott to cut 1,900 jobs amid 'significant headwinds'

By

Abbott will trim its workforce by approximately 1,900 positions in a restructuring exercise intended to streamline commercial and manufacturing operations. Abbott's US pharmaceutical business will shoulder most of the job cuts, which will happen over the next several years, a company spokesperson said.

Pfizer CEO Jeff Kindler steps down, biopharma head Ian Read steps up

Pfizer CEO Jeff Kindler steps down, biopharma head Ian Read steps up

By

Pfizer announced on Sunday that CEO Jeff Kindler has retired from the company, and that Ian Read, Pfizer's head of biopharmaceutical operations, will step into the role as president, CEO and director.

Novartis axing 1,400 US sales jobs due to product changes

By

Effective January 1, Novartis will reduce its US field force by 1,400 positions, the firm said, as it braces for patent expiries and shifts resources for product launches.

Roche details job cuts, passes Tamiflu to contract sales org

By

Roche detailed its "operational excellence" cost-cutting program in a statement today, which includes a reduction of 2,650 pharmaceutical sales and marketing jobs. In total, 6,300 jobs will be affected by the restructuring.

Sanofi-Aventis to cut 1,400 sales reps

By

Sanofi-Aventis will winnow its US sales forces down by 1,400, the company announced on Friday. The move follows layoffs in April of around 400 reps, and brings the total sales force headcount down to roughly 4,000. The Paris-based company employed approximately 6,500 US-based reps just one year ago.

Co-promotion deal gone bad: Cypress hands Savella over to Forest

Co-promotion deal gone bad: Cypress hands Savella over to Forest

By

California-based Cypress Bioscience ended its co-promotion agreement with Forest Laboratories on Savella (milnacipran), a fibromyalgia drug approved in January 2009. As a result, Cypress will cut 123 jobs.

Novartis announces new changes to US pharma biz

By

Following a full-scale realignment of its commercial model in 2009, Novartis will make new adjustments to its US pharmaceutical operations, including a change at the top: Ludwig Hantson, CEO and head of North American pharmaceuticals, will exit the company, a Novartis spokeswoman confirmed.

Ax falls at Merck as CEO talks sales cuts

By

Eight weeks after the completion of Merck's merger with Schering-Plough, the new company is making staff cuts while hinting of more in commercial and manufacturing areas.

Sanofi-Aventis sales cuts come due

By

Sanofi-Aventis is laying off 750, or nearly 12%, of its US sales reps, as the firm retrenches in the face of generic exposure on some of its lead products.

IMS Health restructuring after dismal Q2

By

IMS Health announced a streamlining of business operations in the wake of second quarter losses, which may include as many as 850 job losses.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.